Hepatitis c virus replicons and replicon enhanced cells
CA 2434845 C · Owner: De Francesco, Raffaele · Inventors: Migliaccio, Giovanni; Paonessa, Giacomo; De Francesco, Raffaele
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention features nucleic acid containing one or more adaptive mutations, and HCV replicon enhanced cells. Adaptive mutations are mutations that enhance HCV replicon activity. HCV replicon enhanced cells are cells having an increased ability to maintain an HCV replicon.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 16, 2002 and granted November 19, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 16, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 16, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.